(1.37%) 5 133.44 points
(1.29%) 38 718 points
(2.17%) 16 184 points
(-1.10%) $78.08
(5.85%) $2.15
(-0.05%) $2 308.50
(-0.70%) $26.64
(0.14%) $963.90
(-0.37%) $0.929
(-1.18%) $10.86
(-0.13%) $0.797
(0.36%) $91.46
Live Chart Being Loaded With Signals
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC...
Stats | |
---|---|
本日の出来高 | 195 682 |
平均出来高 | 126 358 |
時価総額 | 134.75B |
EPS | DKK20.18 ( 2024-05-02 ) |
次の収益日 | ( DKK11.83 ) 2024-08-01 |
Last Dividend | DKK0 ( N/A ) |
Next Dividend | DKK0 ( N/A ) |
P/E | 31.24 |
ATR14 | DKK1.964 (0.10%) |
ボリューム 相関
Genmab A/S 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Genmab A/S 相関 - 通貨/商品
Genmab A/S 財務諸表
Annual | 2023 |
収益: | DKK16.47B |
総利益: | DKK16.25B (98.63 %) |
EPS: | DKK66.64 |
FY | 2023 |
収益: | DKK16.47B |
総利益: | DKK16.25B (98.63 %) |
EPS: | DKK66.64 |
FY | 2022 |
収益: | DKK14.60B |
総利益: | DKK14.60B (100.00 %) |
EPS: | DKK83.38 |
FY | 2021 |
収益: | DKK8.48B |
総利益: | DKK0.00 (0.00 %) |
EPS: | DKK46.00 |
Financial Reports:
No articles found.
Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。